QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AVTR

QT74Avantor, Inc.
NYSE·Healthcare·Medical - Instruments & Supplies·USA
Latest market price
9.58
+0.12+1.27%
OverviewShort InterestFilings
AVTRQT74Avantor, Inc.·NYSE
OverviewShort InterestFilings
9.58+1.27%
TA
Loading chart...
Screen all →
BDX+1.67%$143.98ALC+0.84%$64.68MDLN-1.32%$35.94WST+1.35%$327.95COO+1.32%$65.91BAX+2.58%$19.89ATR+0.28%$120.32RGEN-1.15%$132.02
Snapshot
Index-P/E-EPS (ttm)-0.80
Insider Own5.52%
Shs Outstand682.76M
Perf Week-0.83%
Market Cap6.46BForward P/E11.24EPS next Y0.85Insider Trans0.05%Shs Float-Perf Month25.39%
Enterprise Value10.07BPEG0.23EPS next Q0.19Inst Own-Short Float-Perf Quarter25.89%
Income-555387382.00P/S1.00EPS this Y198.53%Inst Trans-Short Ratio-Perf Half Y-14.46%
Sales6.55BP/B1.16EPS next Y8.15%ROA-4.73%Short Interest-Perf YTD-16.40%
Book/sh8.19P/C11.32EPS next 5Y7.17%ROE-9.59%52W High15.93 -39.86%Perf Year-27.15%
Cash/sh0.41P/FCF14.89EPS past 3/5Y-ROIC-2.70%52W Low7.27 31.77%Perf 3Y-
Dividend Est.-EV/EBITDA79.36Sales past 3/5Y-4.46% 0.49%Gross Margin32.13%Volatility2.58% 3.21%Perf 5Y-
Dividend TTM-EV/Sales1.54EPS Y/Y TTM-18.27%Oper. Margin-4.25%ATR (14)0.42Perf 10Y-
Dividend Ex-Date-Quick Ratio1.17Sales Y/Y TTM-3.42%Profit Margin-8.42%RSI (14)60.21Recom3.11
Dividend Gr. 3/5Y-Current Ratio1.76EPS Q/Q-26.09%SMA204.50%Beta1.37Target Price9.17
Payout0.00%Debt/Eq0.68Sales Q/Q0.00%SMA5012.66%Rel Volume0.82Prev Close9.46
Employees13,500LT Debt/Eq0.70EarningsAug 07SMA200-8.91%Avg Volume9.81MPrice9.58
IPO DateMay 17, 2019Option/ShortYes / YesEPS/Sales Surpr.6.25% 2.53%Net Debt/EBITDA27.87Volume8,042,175Change1.27%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-01-26ReiteratedWolfe Research$7.00
May-14-26ResumedRBC CapitalSector Perform$9.00
Mar-06-26DowngradeBarclaysEqual Weight → Underweight
Feb-13-26ReiteratedMorgan StanleyEqual Weight$12 → $10
Feb-12-26ReiteratedUBSNeutral$13 → $11
Feb-12-26ReiteratedStifel NicolausHold$12 → $10
Feb-12-26ReiteratedJefferiesUnderperform$9.00 → $8.00
Feb-12-26ReiteratedRobert W. Baird$15 → $11
Feb-12-26ReiteratedBarclaysEqual Weight$12 → $9.00
Feb-11-26ReiteratedEvercore ISI$12 → $10
Latest News
Jun-17-26
Jun-17-2609:59AM
Avantor (AVTR) Gets Underperform Rating From Wolfe ResearchYahoo
Jun-16-26
Jun-16-2602:09PM
1 Healthcare Stock for Long-Term Investors and 2 We Turn DownYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue6,5526,5526,784
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A4,4474,4134,504
Gross Profit2,1062,1392,279
Selling, General and Administrative Excl. Other1,2071,5961,641
Research and Development
000
Other Operating Expense1,177790-446
Operating Income-279-2461,085
Interest Expense182170219
Unusual Expense
———
Non-Operating Income (Expense)112512
Net Income Before Taxes-470-441854
Income Taxes7989142
Consolidated Net Income-552-530712
Net Income From Continuing Operations-552-530712
Net Income-552-530712
EPS (Recurring)-0.80-0.781.05
EPS (Basic, Before Extraordinaries)-0.80-0.781.05
EPS (Diluted)-0.80-0.781.04
EBITDA1271391,478
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio0.991.19—
Gross Margin32.1432.6533.59
Operating Margin-4.26-3.7515.99
Net Margin-8.42-8.0910.50
Shares Outstanding678678680
Market Capitalization6,4957,770—
Operating Lease Expense
———
Insider Trading Volume
$10.08$9.45$8.82$8.19$7.56● Close Price0.00M0.97M1.94M2.91M3.88MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
LUCIER GREGORY TDirectorMay 08 '26Buy8.3210,00083,20060,000May 11 12:00 AM
Dingemans SimonDirectorMay 01 '26Buy8.1425,000203,50025,000May 05 12:00 AM
MEHRA SANJEEV KDirectorMar 10 '26Buy8.01125,0001,001,250475,000Mar 11 12:00 AM
LUCIER GREGORY TDirectorFeb 19 '26Buy9.1650,000458,00050,000Feb 23 12:00 AM
SUMME GREGORY LDirectorFeb 12 '26Buy9.40100,000940,000400,000Feb 12 12:00 AM
MEHRA SANJEEV KDirectorDec 05 '25Buy11.09350,0003,881,500350,000Dec 09 12:00 AM
Ligner EmmanuelPresident and CEONov 17 '25Buy11.3587,500993,125283,424Nov 17 12:00 AM
SUMME GREGORY LDirectorOct 30 '25Buy11.25100,0001,125,000300,000Oct 31 12:00 AM
SUMME GREGORY LDirectorAug 21 '25Buy12.56100,0001,256,000200,000Aug 22 12:00 AM
Eck Steven WSVP & Chief Accounting OfficerAug 05 '25Sale11.393,47639,59255,068Aug 06 12:00 AM
SUMME GREGORY LDirectorMay 23 '25Buy12.5030,000375,000100,000May 27 12:00 AM
SUMME GREGORY LDirectorMay 22 '25Buy12.6520,000253,00070,000May 22 12:00 AM
SUMME GREGORY LDirectorMay 07 '25Buy12.0025,000300,00050,000May 09 12:00 AM
Massaro Joseph RDirectorApr 29 '25Buy12.308,10099,63035,038Apr 29 12:00 AM
Kang LanDirectorApr 28 '25Buy12.575,00062,85035,215Apr 29 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR